Full Press Release Details
Forward-Looking Statements This presentation contains forward-looking
statements. Such statements reflect the current views of senior management of T2 Biosystems, Inc. ( we , us , our , T2 , T2 Biosystems or the Company ) and include those about T2's goals, strategies, plans, objectives, prospects, milestones, future
operations, business and industry, anticipated product benefits, future events and conditions and potential scenarios. Such statements and those that include the words "expect," "intend," "plan,"
"believe," "project," "forecast," "estimate," "may," "should," "anticipate" and similar statements of a future or forward-looking nature identify forward-looking
statements for purposes of the federal securities laws or otherwise. Forward-looking statements address matters that involve risks and uncertainties. Each forward-looking statement is subject to risks and uncertainties that could cause actual
results to differ materially from those expressed or implied in such statement, including, for example: (i) our status as an early commercial-stage company and expectation to incur losses in the future; (ii) our ability to obtain marketing
authorization from the FDA or regulatory clearance for additional product candidates in the United States or abroad; (iii) the market acceptance of our technology; (iv) our ability to timely and successfully develop and commercialize existing and
future product candidates; (v) our lengthy and variable sales cycle and lack of sales history; (vi) our ability to successfully manage growth; (vii) federal, state and foreign regulatory requirements; (viii) our uncertain future capital needs and
ability to raise future capital; (ix) dependence on third parties; (x) recruiting, training and retaining key personnel; (xi) competitive factors; (xii) manufacturing and other product risks; (xii) risks related to intellectual property; and (xiii)
other risk factors included in our annual report on form 10-K filed with the Securities and Exchange Commission (SEC) on March 23, 2022 and other documents we file with the SEC from time to time. Accordingly, there are or will be important factors
that could cause our actual results to differ materially from those indicated in these statements. The statements made herein speak only as of the date of this presentation. We do not undertake, and specifically disclaim, any obligation to update
Agenda Company Overview - 5 min. John Sperzel, Chairman and CEO
Panel Discussion: Culture-Independent Diagnostics - 30 min. Aparna Ahuja, MD, Chief Medical Officer James Snyder, PhD, DABMM, FAAM Thomas Walsh, MD, PhD Commercial Strategy - 10 min. Brett Giffin, Chief Commercial Officer Product
Company Overview John Sperzel, Chairman and CEO 2022 T2
Our mission is to fundamentally change the way medicine is practiced
Investment Highlights Proprietary Platform Novel Diagnostics Large
Market Opportunity Innovative proprietary Direct from blood ID Initial target market technology platform in 3-5 hours $2 billion+ (magnetic resonance) (culture independent) Established Reimbursement Robust Product Pipeline Commercially Focused U.S.
potential to become standard of care in sepsis management 6
Significant Economic and Human Toll from Sepsis Sepsis is the leading
cost, cause of death, and cause of readmission in U.S. hospitals Sepsis is the #1 cost of U.S. hospitalization 1 ($62 billion annually) Sepsis is the #1 cause of death in U.S. hospitals 2 (270,000 deaths annually) Sepsis is
Disease Control and Prevention.
2022 Corporate Priorities ACCELERATE SALES ENHANCE OPERATIONS ADVANCE
Panel Discussion Aparna Ahuja, MD, Chief Medical Officer James Snyder,
Sepsis Represents $62 Billion in U.S. Healthcare Costs 2,3 Claims more
U.S. lives each year than the top three cancers combined: lung, colorectal, breast Costs the U.S. Causes the death of Claims more lives each healthcare system nearly 270,000 year than the three top 1 2 $62 billion annually Americans annually cancers
combined (lung, colorectal, 2,3 breast) Hospitalized COVID-19 patients face a 22 percent higher risk of developing sepsis and are 4 113 percent more likely to experience septic shock compared to hospitalized influenza patients 1. Buchman TG, et al.
Sepsis Among Medicare Beneficiaries: 3. The Methods, Models, and Forecasts of Sepsis, 2012-2018. Crit Care Med. 2020 Mar;48(3):302-3188l 2. Centers for Disease Control and Prevention [Internet]. c2020. Sepsis: Clinical Information. Available from:
https://www.cdc.gov/sepsis/clinicaltools/index.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fsepsis%2Fdatareports%2Findex.html; 3. Centers for Disease Control and Prevention [Internet]. c2021. An Update on Cancer Deaths in the United States.
COVID-19 Than for Influenza. Available from: https://ehrn.org/articles/sepsis-and-mortality-rates-are-higher-in- patients-hospitalized-for-covid-19-than-for-influenza
The Challenge of Detecting Sepsis-Causing Pathogens The current
standard is a race against time, relying on empiric probability-based protocols HOUR HOUR HOUR HOUR 0 24 48 72+ Empiric Protocol is only optimal in 30-60% of cases Broad Spectrum Antibiotics Each hour of delayed treatment increases mortality risk by
7.6% during Multiple Additional antibiotics/ Additional antibiotics/ Additional antibiotics/ 1 Septic Shock Cultures antifungals delivered antifungals delivered antifungals delivered Blood sample Average time for Blood sample is drawn blood
culture-based Is incubated identification 1. Kumar, A., Roberts, D., Wood, K.E., et al, (2006). Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of 2022 T2 Biosystems. All Rights
Reserved. survival in human septic shock. Critical care medicine, 34(6), 1589-1596. 11
Rapid Detection of Sepsis-Causing Pathogens is Critical T2 Biosystems
provides species and resistance gene identification directly from whole blood within 3-5 hours of the first blood draw, often before the second dose of broad-spectrum antibiotics is delivered, enabling clinicians to achieve targeted therapy faster
Novel Culture-Independent BSI and AMR Diagnostics Fully-automated T2Dx
Instrument, Sepsis Test Panels and SARS-CoV-2 Panel Rapid: Results in 3-5 hours 1 2 3 4 Sensitivity: 91% Sensitivity: 90% Sensitivity: 99% PPA: 95% 2 3 4 1 2 Specificity: 98% Specificity: 99% NPA: 100% Easy-to-use: Specificity: 99%
Se9.4% 4 PPA: 95% No sample preparation required mecA/C Detects all 4 NPA: 100% C. albicans E. faecium emerging variants** vanA/B Sensitive and Specific: C. tropicalis S. aureus CTXM-14/15 900 GE/mL - ~1 CFU/mL LoD and >98% Specificity C.
parapsilosis K. pneumoniae contrived KPC C. krusei P. aeruginosa OXA-48 Group 2000 GE/mL - C. glabrata E. coli patient samples NDM, VIM, IMP AmpC (CMY/DHA) FDA-Cleared RUO* (US only) FDA - For Emergency FDA-Cleared CE-marked CE-marked
CE-marked Use Authorization only 1-3 CFU/mL LoD 2-11 CFU/mL LoD 3-11 CFU/mL LoD **alpha, beta, gamma, delta, lambda, mu, iota, omicron *T2Resistance is not FDA cleared 1. Mylonakis E, et al. T2 magnetic resonance assay for the rapid diagnosis of
accuracy study. Ann Intern Med. 2019 Jun 13 18;170(12):845-852; 3. T2Resistance data on file; 4. T2SARS-CoV-2 data on file.
Meta-analysis of 14 Controlled Studies (Peer-Reviewed) Highlights
benefits of T2 Biosystems sepsis technology vs. blood culture Title: Antimicrobial and Resource Utilization with T2 Magnetic Resonance for Rapid Diagnosis of Bloodstream Infections: Systematic Review with Meta-analysis of Controlled Studies (2021)
Authors: Maddalena Giannella, George A. Pankey, Renato Pascale, Valerie M. Miller, Larry E. Miller, Tamara Seitz Journal: Expert Review of Medical Devices Seven Outcomes Evaluated Time to detection 81 hours faster with T2MR Time to
species identification 77 hours faster with T2MR Patients testing positive on T2MR received targeted antimicrobial therapy 42 hours faster Patients testing negative on T2MR de-escalated from empirical therapy 7 hours faster
Length of ICU stay 5 days shorter with T2MR Length of hospital stay 4.8 days shorter with T2MR Mortality rates were comparable between T2MR and BC Giannella M, et al. Antimicrobial and resource utilization with T2 magnetic resonance
Panel Discussion: Culture-Independent Diagnostics 2022 T2
Commercial Strategy Brett Giffin, Chief Commercial Officer 2022
Commercial Strategy Increase instrument installed base and expand
sepsis testing UNITED STATES MARKET INTERNATIONAL MARKET - Installed base: 90 T2Dx Instruments - Installed base: 55 T2Dx Instruments - Sales force expansion - Sales force expansion - Enhanced training programs - Geographic expansion (EU/ME, APAC,
LATAM) - Instrument placement programs - Enhanced distributor training and support - Transition COVID-driven instruments to sepsis testing Collaboration with Medical Affairs to increase sepsis test utilization and clinical value awareness
Growing Independent Support for T2 Technology Included in dozens of
independent, real-world clinical case studies demonstrating clinical utility of T2Bacteria and T2Candida (www.t2biosystems.com) TM U.S. Food & Drug Administration granted breakthrough device designation for T2Resistance Panel U.S. Centers
for Medicare & Medicaid Services (CMS) established T2Bacteria as first diagnostic product to gain incremental reimbursement through its New Technology Add-on Payment (NTAP) U.S. Department of Health and Human Services (i.e., BARDA) awarded T2
Biosystems with up to $69 million in milestone-based product development funding Vizient, Inc. awarded T2 Biosystems with Innovative Technology contract, providing access to more than 50 percent of the nation's acute care hospitals, 95 percent
Implementation Strategy Execution - Sales, Medical Affairs, Service
Education Implementation Identify Use Cases Routine Testing Clinical and economic value Patient selection criteria: Secure approval for go-live and Establish patient sample and incorporation into sepsis protocol proposition Hematology/Oncology, ICU,
Product Pipeline Roger Smith, Senior VP Science R&D 2022 T2
T2 Biosystems' Product Pipeline Product Name Collaborator Phase I
Phase II Phase III Phase IV Phase V (Feasibility) (Development) (Verification) (Clinical/Regulatory) (Commercial Launch) Initiated U.S. Trial Launched (EU) - CE mark T2Resistance Panel BARDA (Q4 2021) Initiated U.S. Trial T2Biothreat
T2Resistance Panel The first direct-from-blood detection of
antibiotic resistance markers Detection of 13 antibiotic resistance genes from Covers the most clinically important antibiotic both Gram-positive and Gram-negative pathogens resistance pathogens direct-from-blood, without the wait
for blood culture - Carbapenem-resistant Acinetobacter - Carbapenem-resistant Enterobacteriaceae (CRE) Performed on the T2Dx Instrument with results in 3-5 - Extended-spectrum Beta-lactamase (ESBL) producing hours Enterobacteriaceae
Obtained CE Mark and launched in Europe - Vancomycin-Resistant Enterococci (VRE) - Methicillin-Resistant S. aureus (MRSA) Granted "Breakthrough Device" designation by FDA The CDC estimates that these infections
result in Initiated U.S. clinical trial in December 2021 over 590,000 hospitalizations and 25,000 deaths 1 annually in the US Proposed submission to FDA in 2022 ~46% of patients are given inappropriate empiric therapy, many
associated with antimicrobial resistance 2 infections Rapid diagnosis of patients with resistance infections is essential to getting them on appropriate therapy and 2 reducing mortality 1.
efficacy of appropriate empiric antibiotic therapy for sepsis. Antimicrob Agents Chemother. 2010;54(11):4851-4863. doi:10.1128/AAC.00627-10
T2Biothreat Panel Novel direct-from-blood detection of biothreat
pathogens 1 Simultaneously detects 6 biothreat pathogens direct-from-blood, without the wait for blood culture Proposed to be an aid in the diagnosis of anthrax, tularemia, melioidosis, glanders, typhus fever and plague
Bioterrorism is a real threat to U.S. security - 1984 - Russia was reported to have used bioterrorism in Afghanistan - 2001 - U.S. congressional members attacked with anthrax - over 22 illnesses and 5 deaths - 2022 - U.S. Government warns of
potential use of biological weapons by Russia in Ukraine Based on reported data, the panel is expected to be more sensitive than other FDA cleared molecular tests Proposed submission to FDA in 2022 2022 T2 Biosystems. All
Rights Reserved. 1. Noted by the CDC to be Category A or B biothreat agents 23
Comprehensive Panel Bloodstream Infections (BSI) and Antimicrobial
Resistance (AMR) Direct-from-blood test panel with results in approximately 3 hours Detects a combination of genus, complex, species and resistance markers Proposed to detect >95% of blood stream infections from a single
blood sample Market Research: Infectious Disease Physician and Pharmacist Responses "I think this is very exciting technology and I would be excited to have something like that brought on to my institution, so I could definitely see this
advantageous for having available for our sepsis patients." "..is this [comprehensive panel] helpful to me as a clinician for faster treatment and antimicrobial stewardship? - There is no doubt!" "I could see broad
Next-Generation Instrument Design specifications Random access,
fully-automated system able to process multiple samples simultaneously Designed in parallel with comprehensive panel for BSI and AMR Requires no up-front sample processing Processes whole blood samples Utilizes a
Financial Summary John Sprague, Chief Financial Officer 2022 T2
Financial Summary 1 2022 Guidance 2021 2020 % Change 55% Total Revenue
$28-31 million $28.1 million $18.1 million 42% Product Revenue $16-17 million $16.6 million $11.7 million 78% R&D Revenue $12-14 million $11.4 million $6.4 million T2Dx Instruments 60-70 32 57 2 Cash Balance $33.8 million 1. Guidance assumes a
Q&A T2 Biosystems Management Team 2022 T2 Biosystems. All